Prostate is an immune-competent organ normally populated by inflammatory cells. Prostatic inflammation origin can be multi-factorial and there are some emerging evidences on its possible role as a factor involved in prostate cancer (PC) pathogenesis and progression. This review critically analyzes the role of inflammation as a prognostic factor for progression and aggressiveness of PC. We verified the last 10 years literature data on the association between inflammation and PC aggressiveness, or PC response to therapies. Several studies tried to correlate different inflammatory factors with the aggressiveness and metastatization of PC; all data sustain the role of inflammation in PC progression but they also produce confusion to identify a reliable clinical prognostic marker. Data on patients submitted to radical prostatectomy (RP) showed that cases with marked intraprostatic tissue inflammation are associated with higher rate of biochemical progression; systemic inflammation markers appear to have a significant prognostic value. Analyzing data on patients submitted to radiotherapy (RT) emerges a significant association between high neuthrophil to lymphocyte ratio (NLR) and decreased progression free survival and overall survival; also plateled to lymphocyte ratio (PLR) and C-reactive protein (CRP) have been proposed as significant prognostic factors for progression and overall survival. In patients submitted to androgen deprivation therapy (ADT), inflammation may drive castration resistant PC (CRPC) development by activation of STAT3 in PC cells. NLR has been proposed as independent predictor of overall survival in CRPC submitted to chemotherapy. Most of data are focused on markers related to systemic inflammation such as NLR and CRP, more than specifically to chronic prostatic inflammation. The suggestion is that these inflammatory parameters, also if not specific for prostatic inflammation and possibly influenced by several factors other than PC, can integrate with established prognostic factors.

Prognostic value of inflammation in prostate cancer progression and response to therapeutic: A critical review / Sciarra, Alessandro; Gentilucci, Alessandro; Salciccia, Stefano; Pierella, Federico; DEL BIANCO, Flavio; Gentile, Vincenzo; Silvestri, Ida; Cattarino, Susanna. - In: JOURNAL OF INFLAMMATION. - ISSN 1476-9255. - STAMPA. - 13:1(2016), pp. 1-11. [10.1186/s12950-016-0143-2]

Prognostic value of inflammation in prostate cancer progression and response to therapeutic: A critical review

SCIARRA, Alessandro;GENTILUCCI, ALESSANDRO;SALCICCIA, STEFANO;PIERELLA, FEDERICO;DEL BIANCO, FLAVIO;GENTILE, Vincenzo;SILVESTRI, Ida;CATTARINO, SUSANNA
2016

Abstract

Prostate is an immune-competent organ normally populated by inflammatory cells. Prostatic inflammation origin can be multi-factorial and there are some emerging evidences on its possible role as a factor involved in prostate cancer (PC) pathogenesis and progression. This review critically analyzes the role of inflammation as a prognostic factor for progression and aggressiveness of PC. We verified the last 10 years literature data on the association between inflammation and PC aggressiveness, or PC response to therapies. Several studies tried to correlate different inflammatory factors with the aggressiveness and metastatization of PC; all data sustain the role of inflammation in PC progression but they also produce confusion to identify a reliable clinical prognostic marker. Data on patients submitted to radical prostatectomy (RP) showed that cases with marked intraprostatic tissue inflammation are associated with higher rate of biochemical progression; systemic inflammation markers appear to have a significant prognostic value. Analyzing data on patients submitted to radiotherapy (RT) emerges a significant association between high neuthrophil to lymphocyte ratio (NLR) and decreased progression free survival and overall survival; also plateled to lymphocyte ratio (PLR) and C-reactive protein (CRP) have been proposed as significant prognostic factors for progression and overall survival. In patients submitted to androgen deprivation therapy (ADT), inflammation may drive castration resistant PC (CRPC) development by activation of STAT3 in PC cells. NLR has been proposed as independent predictor of overall survival in CRPC submitted to chemotherapy. Most of data are focused on markers related to systemic inflammation such as NLR and CRP, more than specifically to chronic prostatic inflammation. The suggestion is that these inflammatory parameters, also if not specific for prostatic inflammation and possibly influenced by several factors other than PC, can integrate with established prognostic factors.
2016
Hormone therapy; Inflammation; Prostate neoplasm; Radical prostatectomy; Radiotherapy; Clinical Biochemistry; Cell Biology
01 Pubblicazione su rivista::01a Articolo in rivista
Prognostic value of inflammation in prostate cancer progression and response to therapeutic: A critical review / Sciarra, Alessandro; Gentilucci, Alessandro; Salciccia, Stefano; Pierella, Federico; DEL BIANCO, Flavio; Gentile, Vincenzo; Silvestri, Ida; Cattarino, Susanna. - In: JOURNAL OF INFLAMMATION. - ISSN 1476-9255. - STAMPA. - 13:1(2016), pp. 1-11. [10.1186/s12950-016-0143-2]
File allegati a questo prodotto
File Dimensione Formato  
Sciarra_Prognostic-value_2016.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 453.07 kB
Formato Adobe PDF
453.07 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/915648
Citazioni
  • ???jsp.display-item.citation.pmc??? 35
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 49
social impact